SCITECH DEVELOPMENT
SciTech Development is a specialty pharmaceutical company dedicated to advancing cancer treatment with a revolutionary new Drug Delivery Platform (SDP) that engineers new therapeutics for broader and better clinical outcomes. Our patented and lead drug candidate ST-001 nanoFenretinide is a combination of SDP with the promising cancer drug fenretinide.
SCITECH DEVELOPMENT
Industry:
Biotechnology Life Science Pharmaceutical
Address:
Grosse Pointe Farms, Michigan, United States
Country:
United States
Website Url:
http://www.scitechsdp.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Leadiant Biosciences
Leadiant Biosciences is a pharmaceutical company dedicated to the development, registration and commercialization of effective therapies.
Current Advisors List
Current Employees Featured
Official Site Inspections
http://www.scitechsdp.com Semrush global rank: 4.41 M Semrush visits lastest month: 1.36 K
- Host name: ecngx303.inmotionhosting.com
- IP address: 168.235.116.114
- Location: Atlanta United States
- Latitude: 33.8336
- Longitude: -84.3797
- Metro Code: 524
- Timezone: America/New_York
- Postal: 30305
More informations about "SciTech Development"
About - Invest in SciTech SDP & ST-001 nanoFenretinide
SciTech Development LLC was formed in Michigan as a spin-off from the Karmanos Cancer Institute (KCI) and Wayne State University (WSU). As a recipient of a U.S. Small Business Innovation Research (SBIR) grant, …See details»
SciTech Development - Crunchbase Company Profile
Organization. SciTech Development . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ...See details»
SciTech Development | Fenretinide | nanoFenretinide
SciTech is Advancing Cancer Treatment Through Safer Drug Delivery - SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing cancer treatment with a revolutionary new Drug Delivery Platform (SDP) that …See details»
Team - Invest in Experienced Team at SciTechSDP
Often the difference between success and failure is the dedication and persistence of the executive team. SciTech Development’s principal assets, the Delivery Platform (SDP) and …See details»
Investors - scitech
Revolutionary Drug Delivery Platform (SDP) that engineers new therapeutics for broader and better clinical outcomes. Our patented lead drug candidate ST-001 nanoFenretinide is a …See details»
SciTech Development - Craft
SciTech Development is a clinical-stage oncology pharmaceutical company that provides cancer treatment services. It offers ST-001 nanoFenretinide, a formulation in clinical trials for T-cell …See details»
Contact Us | SciTech Development | Fenretinide | nanoFenretinide
Contact us to learn more about our lead drug ST-001 nanoFenretinide, drug product pipeline, proprietary technology and investment and partnering opportunities; follow us on social media.See details»
SciTech Development - Products, Competitors, Financials, …
About SciTech Development. SciTech Development focuses on advancing cancer treatment through safer drug delivery. The company's main offering is a new Drug Delivery Platform …See details»
SciTech Development Announces IRB Approval for Human Clinical …
SciTech Development ("SciTech" or the "Company"), a clinical-stage pharmaceutical company with a novel and patented drug delivery platform, today announced that the company has …See details»
Why Invest In SciTech - Cost-Effective Value-Based Medicine
Invest Now in low-risk, value-based medicine, many exits, patented drug Delivery Platform SDP & candidate ST-001 nanoFenretinide FDA approved to enter clinic.See details»
SciTech Development Announces IRB Approval for Human
Sep 14, 2023 For more information about the Company, please visit: https://SciTechSDP.com Safe Harbor - Forward-Looking Statement: This document contains certain forward-looking …See details»
SciTech Development Team | scitech
Revolutionary Drug Delivery Platform (SDP) that engineers new therapeutics for broader and better clinical outcomes. Our patented lead drug candidate ST-001 nanoFenretinide is a …See details»
SciTech Development Announces First Patient Dosed in Phase 1 …
GROSSE POINTE, Mich., Dec. 20, 2023 /PRNewswire/ -- SciTech Development ("SciTech" or the "Company"), a clinical-stage pharmaceutical company with a novel and patented drug delivery …See details»
Contact SciTech - Invest in SDP & ST-001 Drug Opportunity
Connect & invest now in SciTech Development, a specialty pharmaceutical company; for more detailed info about our science, visit www.SciTechDevelopment.com.See details»
Meet Earle Holsapple, the driving... - SciTech Development
Meet Earle Holsapple, the driving force behind SciTech Development's transformative journey. As our CEO and President/Co-Founder, his dynamic leadership has propelled our mission of …See details»
SciTech Announces Equity Crowdfunding Launch
SciTech Development LLC, a specialty pharmaceutical company, announces the launch of its equity crowdfunding campaign on StartEngine. SciTech is seeking investment funding to grow …See details»
News & Events - SciTechSDP & ST-001
A clinical-stage, specialty oncology pharmaceutical company. Revolutionizing how safe and promising yet challenged drugs can be delivered to kill cancer.See details»
Science - Invest in SciTech’s Drug Delivery Platform SDP
Our accelerated, Phase 1 clinical trial utilizes ST-001 nanoFenretinide for the treatment of T-cell lymphomas. (ClinicalTrials.gov Identifier: NCT04234048). Our goal is to confirm that:See details»
Clinical Trial | nanoFenretinide | Fenretinide | SciTech Development
Phase 1 Clinical Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma ClinicalTrials.gov Identifier: NCT04234048See details»